Stephen Faraone

Stephen Vincent Faraone (born July 27, 1956) is an American psychologist. He has worked mainly on attention-deficit hyperactivity disorder and related disorders.
Education and career.
Faraone graduated in 1978 from the State University of New York at Stony Brook with a BA in Psychology. He then went to the University of Iowa where he obtained his Master of Arts and Doctor of Philosophy. Faraone completed a postdoctoral clinical psychology internship and a research fellowship at Brown University.
After completing his post-doctoral fellowship at Brown, Faraone came to the Harvard Department of Psychiatry, where he began a career in psychiatric genetics. He first served as an instructor in 1985, and as an assistant professor in 1989. He was promoted to associate professor in 1993 and Full Professor in 2002. In 2004 he moved to SUNY Upstate Medical University where he is now Distinguished Professor of Psychiatry and of Neuroscience and Physiology. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Faraone has been principal investigator on several National Institutes of Health funded grants studying the nature and causes of mental disorders in childhood. He is one of the world's leading authorities on the genetics of psychiatric disorders and has also made substantial contributions to research in psychopharmacology and research methodology.
Awards and honors.
Faraone has authored over 700 journal articles, editorials, chapters, and books and was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI). In 2005, ISI determined him to be the second highest cited author in the area of ADHD and in 2007, he was the third most highly cited researcher in psychiatry for the preceding decade. From 2014 to 2019 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics.  In 2019 and 2002, his citation metrics placed him in the top 0.01% of scientists across all fields 
In 2002, Faraone was inducted into the CHADD Hall of Fame in recognition of outstanding achievement in medicine and education research on attention disorders. In 2004 and 2008, Faraone was elected Vice President of the International Society of Psychiatric Genetics and in 2019 he received the Paul Hoch Award from the American Psychopathological Association. In 2008, he received the SUNY Upstate President's Award for Excellence and Leadership in Research. In 2019 he was elected President of the World Federation of ADHD 
Research Funding and Financial Disclosures.
Faraone's research has been funded by the National Institute of Health, the European Union and the following pharmaceutical companies: Shire/Takeda, Ironshore, McNeil, Janssen and Sunovion. He has received income income from Shire, Rhodes, KenPharm, McNeil, Janssen, Pfizer, Eli Lilly, Sunovion, Ironshore and Novartis. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. These disclosures are routinely reported in relevant publications